Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phytopica
- Development stage
- Preclinical
- Lead developer
- IXICO
- Administration
- Oral
01
Overview
**Phytopica** is an oral veterinary botanical product originally developed by Phytopharm for canine skin health and atopic dermatitis. It is a proprietary, chemically heterogeneous blend of standardized plant extracts rather than a single defined molecular entity. In a randomized, double-blind, placebo-controlled 12-week study in 120 dogs with perennial canine atopic dermatitis, the product code **PYM00217** produced a statistically significant reduction in CADESI disease-severity scores at 200 mg/kg/day; no serious adverse effects were reported, although mild gastrointestinal events occurred more frequently at higher doses. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/16827666/))
- Brand names
- Phytopica
- Other names
- PhytopicaTM
Beyond the preview
Go deeper on Phytopica.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Phytopica.